InvestorsHub Logo
Followers 47
Posts 2742
Boards Moderated 0
Alias Born 02/06/2017

Re: survivor1x post# 305104

Sunday, 09/06/2020 9:59:06 AM

Sunday, September 06, 2020 9:59:06 AM

Post# of 720874

Merck characterizes the measure, "tissue tumor mutational burden-high," or TMB-H, as tumors with at least 10 mutations per megabase or greater, which would be determined via an FDA-approved test. And Merck, incidentally, is leaning on evidence from the same Keynote-158 study that led to its first tissue-agnostic approval in 2017. Updated evidence from the study last year showed higher response rates to Keytruda for people with TMB-high tumors than others.



Replace tumor mutational burden with SUB-TYPE and Direct is
Good to Go .......

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News